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Age-related macular degeneration (AMD) is a progressive eye disease that affects 
the macula, causing blurred central vision making it difficult for diagnosed patients to 
see fine details and have trouble with everyday tasks. Recent studies have suggested 
that blue light is able to cause damage to eyes that progresses to AMD. Exposure of blue 
light to our eyes is a growing concern in our everyday lives due to the prevalence of 
computers, phones, and tablets. Blue light is responsible for cell damage, cell death, and 
oxidative stress, all of which can lead to vision loss. Resveratrol and pterostilbene are 
polyphenols found in the skin of various fruits including grapes and blueberries and 
have been well studied for their antioxidant properties. The aim of this study was to 
investigate the biological activity of resveratrol and pterostilbene on cell viability (MTS 
assay), cell death markers (Caspase-3/7 activity, Caspase-3 protein expression and 
Propidium Iodide assay), antioxidant potential (catalase and MnSOD), and the levels of 
oxidative stress (4HNE),  in retinal pigment ARPE-19 cells exposed to blue light. ARPE-
19 cells were incubated with a pre-treatment of 50µM and 100µM of resveratrol or 
10µM and 250µM of pterostilbene for 4 hours followed by the exposure of blue light 
(475nm) for 12 hours. Blue light exposure on ARPE-19 cells resulted in a 56% reduction 
(p<0.0001) in cell viability along with an increase in caspase 3/7 activation, and a 50% 
increase (p<0.0001) in cell necrosis. This was accompanied by an increase in protein 
adduct formation of  4HNE and protein expression of antioxidants such as, catalase, 
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and MnSOD. Resveratrol treatment of 50µM was able to maintain cell viability by 37% 
(p<0.05), and significantly (p<0.05) reduced the caspase 3/7 fluorescence activity when 
compared to control cells exposed to blue light. Cellular necrosis was also significantly 
reduced (p<0.05) by both 50µM and 100µM treatments of resveratrol. In conclusion, the 
damaging effects of blue light was mitigated by treatments of resveratrol in ARPE-19 
cells. Pterostilbene treatments of 10 and 25µM were unable to maintain cellular viability 
across both MTS assay and caspase 3/7 fluorescence assay. Both concentrations showed 




This research project was part of the human sciences, specifically in regard to the 
study of Age-Related Macular Degeneration (AMD). It set out to investigate two 
naturally occurring polyphenols from grapes and berries, resveratrol and pterostilbene, 
and their role in offering protection against  damage caused by blue light and slowing 
down the progression of blue light induced AMD. By analyzing the results from 
various assays, it was concluded that blue light is able to cause significant damage to 
eye cells. Resveratrol was able to attenuate damages caused by blue light whereas 
pterostilbene was less effective. Future studies are directed towards investigating the 
role of these phenolic compounds in combination with currently used AMD treatments 
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1.1 The Eye 
 
 The human eye has many parts which work together towards the central goal of 
completing vision. The front portion of the eye is made up of the cornea, iris, pupil, and 
lens which work together to help focus the light entering the eye onto the back portion 
of the eye, the retina. When light enters the eye, the cornea bends the rays in order for 
them to pass through the circular pupil. The iris opens and closes to regulate the 
amount of light entering the eye. The light then passes through the lens which is able to 
further bend and change the shape in order to focus them on the retina (Figure 1.1). The 
retina is a thin layer of tissue that contains millions of light sensing nerve cells called 
rods and cones (Figure 1.2).   
 
Figure 1.1. Anatomy of the Human Eye: The basic structure of the human eye. Figure 




Figure 1.2: Layers of the Human Retina Human retinal layers shown in relation to the 
macula of the eye. Figure adapted from Al Gwairi, O., et al. 2016. 
 
Photoreceptors are specialized cells within the retina that respond to light, three 
types of photo receptors are known, rods, cones, and photosensitive retinal ganglion 
cells (pRGC). Rods are located outside the macula and extend to the outer edge of the 
retina. Rods allow for peripheral vision as well as assist in motion detection and low 
light vision. Cones are concentrated at the center of the retina in the macula. Cones 
allow for vision in bright conditions while also detecting color and fine details. 
Posterior to the photoreceptors there is a very thin layer of cells called the  
Retinal Pigment Epithelial (RPE) cells, which are part of the blood-ocular barrier. RPE 
cells function to (1) transport nutrients, ions, vitamins, and water, (2) absorb light and 
protect against photooxidation, (3) convert trans-retinal into 11-cis-retinal, which is 
essential for the vision cycle, (4) phagocytosis shed of photoreceptor membrane, and (5) 
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to secrete essential factors for structural integrity of the retina (Crabb, J. W., et al. 2002, 
Jager, R. D. et al. 2008, Simó, R., et al. 2010). 
The choroid is made up of a layer of blood vessels that supply oxygen and 
nutrients to the retina. Bruch’s membrane functions to separate the retina from the 
choriocapillaris and also is a vital transport membrane of nutrients and metabolic waste 
from the RPE cells and photoreceptors (Strauss, O. 2005). Oxygen, electrolytes, nutrients 
and growth factors destined for RPE cells pass through the choriocapillaris and across 
Bruchs’s membrane to the cells on the other side. Waste from the RPE cells and 
photoreceptors travel across Bruch’s membrane to be eliminated (Abdelsalam, A. et al. 
1999, Curcio, C. A. et al. 2013). 
In higher mammals, the center of the vision field contains a high concentration of 
photoreceptors, known as the macula. The macula is the functional center of the eye and 
is the area where light is focused by the structures in the front portion of the eye, the 
cornea and lens. In general, the macula takes the picture which is then sent through the 
optic nerve to the brain where vision can be completed. The overall structure of the 
macula is important to have good vision, any small disturbance or increased fluid can 
cause deterioration in vision (Jager, R. D. et al.2008). The macula contains the densest 
concentration of photoreceptors within the retina which is responsible for the ability to 
see fine details, read, and recognize faces (Jager, R. D. et al. 2008). 
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1.2 Macular Dysfunction in Dry and Wet Age-Related Macular Degeneration  
 
Age-related macular degeneration (AMD) is a progressive eye condition that 
affects the macula, causing blurred central vision making it difficult for diagnosed 
patients to see fine details and have trouble with everyday tasks such as reading and 
driving (Moutray, T. et al. 2011, Colijn, J. M., et al. 2017). The first change that usually 
occurs is the formation of drusen between the RPE cells and Bruch’s Membrane. Drusen 
deposits are acellular polymorphous debris and are observed during a funduscopic eye 
examination as pale, yellowish regions in both the macula and the retina (Crabb, J. W. et 
al. 2002, Jager, R. D. et al. 2008, Abdelsalam, A. et al. 1999). Drusen formation can range 
from one or two deposits to several hundred, increasing amounts of deposits correlates 
with slow loss in vision acuity (Bressler, N. M. et al. 1988, Jager, R. D. et al.2008). There 
are presently two types of drusen that can be detected in the macula. Hard drusen are 
typically small and are distinctly separated from one another (Tomi, A. et al. 2014). 
They typically do not cause serious distortion of vision in small numbers due to their 
size and separated distribution (Tomi, A. et al. 2014). Soft drusen are typically larger in 
size and can be harder to distinguish due to the less clearly defined borders (Tomi, A. et 
al. 2014). Soft drusen deposits can increase some patients’ risk for developing AMD. 
Both hard and soft drusen develop as a natural process with aging, its exact relationship 
is not fully understood, however, having many soft drusen deposits is a common 
symptom of dry AMD (Bressler, N. M., et al. 1988).  
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In contrast to the slow progressive changes in dry AMD, wet or exudative AMD 
is a rapid changing process. Wet AMD develops when there is the formation of blood 
vessels from the choroid layer into the macula, called choroidal neovascularization 
(Noble, J. et al. 2010, Bressler, N. M., et al. 1988). These abnormal blood vessels can 
easily break and leak fluid and blood into the layers of the retina (Noble, J. et al. 2010, 
Bressler, N. M., et al. 1988). Fluid buildup can collect between the RPE layer and Bruch’s 
membrane causing a bump in the RPE cell (Figure 1.3), altering the shape which leads 
to photoreceptor damage and severe vision loss. Figure 1.3 depicts the structural 
changes that occur in patients diagnosed with AMD.  
 
Figure 1.3. Structural Changes During AMD Progression. A normal retina can be seen 
on far left. Early AMD shows thickening of Bruch’s membrane. Intermediate AMD 
shows small drusen deposits forming. Late Dry AMD shows small and large drusen 
deposits effecting Bruch’s Membrane as well as the RPE cells. Late Wet AMD shows the 
choroidal neovascularization and subretinal fluid accumulation which leads to 






The onset of wet AMD is much more rapid than the dry form; however, it is 
typical for dry AMD to be a precursor to wet AMD (Ambati, J., et al. 2012). Although it 
is typical for dry AMD to occur prior to the wet form, both forms of AMD are not 
mutually exclusive. Figure 1.4 shows the differences seen between wet and dry forms of 
AMD clinically (Acharya, U. R., et al. 2016) 
Figure 1.4: Types of AMD a. Normal image of eye b. Dry form of AMD showing 
drusen formation c. Wet form of AMD showing vascularization of the choroidal layer. 
Image from Acharya, U. R., et al. (2016) 
Vascular endothelial growth factor A (VEGF-A) is a key signaling molecule in 
wet AMD (Noble, J., et al. 2010). When cells are deprived of oxygen, they increase their 
production of VEGF-A. VEGF-A is a protein that induces vascular proliferation and 
migration of endothelial cells from preexisting vessels. In AMD, these blood vessels 
form and can leak fluid into the retina causing interference with the retinal function 
resulting in vision distortedness which may develop within a few days to a few weeks 
(Noble, J., et al. 2010, Bressler, N. M., et al. 1988). VEGF-A is able to bind to either of the 
two VEGF receptors, VEGFR-1 and VEGFR-2 (Shibuya, M. 2011). Both receptors are 
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closely related and share common ligands. VEGFR-1 is a kinase-impaired RTK whereas 
VEGFR-2 is a highly active kinase. Despite their differences, both receptors are required 
for development and angiogenesis.  
AMD is the leading cause of blindness among persons of European-descent over 
the age of 50 and accounts for a total of 8.7% of worldwide blindness (Colijn, J. M., et al. 
2017). The prevalence of AMD is expected to increase by more than 50% in the next 10-
15 years (Colijn, J. M., et al. 2017, Friedman, D. S., et al. 2004, Bressler, N. M., et al. 1988). 
Some of the major risk factors that can predispose an individual to AMD are; smoking, 
obesity, high dietary intake of vegetable fats, and a low dietary intake of antioxidants 
(Jager, R. D. et al. 2008).  
 
1.3 Smoking and AMD  
 
The most significant risk factor for developing AMD after the age of 50 is 
smoking. Studies in the United States, Australia, France and the Netherlands have 
demonstrated a 2.5- to threefold increase in the risk of both wet and dry AMD in 
smokers (Mares, J. A., et al. 2017, Chader, G. J., et al. 2013, Montezuma, S. R., et al. 2007). 
Smoking causes vasoconstriction to the blood vessels which reduces the supply of blood 
and oxygen to the eyes (Frayser, R., et al. 1964). Smoking also introduces many free 
radicals into the body, these cause irreversible cellular damage and depletes the levels 
of antioxidants available to combat free radicals (Cheng, A. C., et al. 2000). Oxidative 
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damage and reduction of local antioxidative enzymes in RPE cells can also decrease 
macular pigment density, which serves as a filter for short-wavelength light (Bonilha, V. 
L. 2008). Cigarette smoke contains many toxic compounds, ocular exposure to these 
compounds can cause oxidative damage, vascular changes, and inflammation leading 
to the pathogenic cascade of AMD (Cheng, A. C., et al. 2000).  
Genetic factors that contribute to the aging of the retina are still being studied 
through microarray technology. Changes in retina gene expression patterns are found 
to be greatly linked to oxidative stress and energy metabolism responses (Montezuma, 
S. R., et al.  2007). Certain ethnic groups such as the Caucasian populations have been 
found to exhibit higher frequencies of the disease than others (Kenney, M. C., et al. 
2013). There are a variety of other studies being conducted currently to try and narrow 
down if AMD has a genetic link within the population.  AMD is most likely 
multifactorial disease which is typically caused by a combination of many genetic 
variants and environmental factors as discussed above like smoking and diet 
(Ratnapriya, R., et al. 2013).  
 
1.4 Treatments for Dry AMD  
Current treatments for AMD are dependent on the stage of the disease. Dry 
AMD is commonly treated with modifiable lifestyle changes. Generally, nutritional 
therapy with a balanced healthy diet with a high vitamin intake and antioxidants 
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support the cells of the macula. If the disease progresses to a further advanced form of 
dry AMD, supplements are commonly prescribed to increase the concentration of 
vitamins and minerals known to support cell health (Bandello, F., et al. 2017). Two 
studies AREDS and AREDS 2 (Age Relates Eye Disorder Studies) illustrated promising 
results that dietary supplements were able to slow down the progression of AMD 
(Chew, E. Y., et al. 2012). AREDS was a randomized clinical trial with over 4000 
patients. These patients received placebo or treatment of dietary supplements 
containing antioxidants, zinc oxide, or a combination of both. Patients who received the 
antioxidants or zinc oxide saw a 17% or 21% risk reduction as compared to the placebo 
group respectively. Patients who received the combination treatment of antioxidants 
and zinc oxide saw a risk reduction of 25% (Age-Related Eye Disease Study Research 
Group. 2003). AREDS2 looked at more patients and a different formulation of 
supplements. Patients were divided into different groups and given either the original 
AREDS formula or the new modified one. Modifications included lutein and 
zeaxanthin, omega-3 fatty acids, or a combination of both. This study showed that 
lutein and zeaxanthin have a strong role in management of AMD and nutritional 
supplements are correlated with a reduction in risk of developing AMD (Chakravarthy, 




1.5 Treatments for Wet AMD 
 
  Since its discovery in the early 1970s, AMD has been a challenging disease to 
treat or cure. Even today in 2020 there is yet to be a cure for AMD and current 
treatments only decrease the rate of disease progression. Originally, laser 
photocoagulation was thought to be a possible treatment for wet AMD (Burgess, D. B., 
et al. 1993). Although studies showed promising results in extrafoveal lesions, 
parafoveal lesions showed less favorable results (Burgess, D. B., et al. 1993). One notable 
study, The Macular Photocoagulation Study was halted prior to completion due to 
many of the patients in the treatment group having a decrease in visual acuity (Macular 
Photocoagulation Study Group. 1991). Today, photocoagulation is rarely used in the 
treatment of AMD due to numerous issues including; vision loss, increased recurrence 
rate, and limited visual improvement (Al-Zamil, W. M., et al. 2017). 
  In the late 1990s photodynamic therapy (PDT) was introduced as a possible 
treatment, and approved by the US food and Drug Administration (FDA) for 
ophthalmic use (Bressler, N. M. 1999, Al-Zamil, W. M., et al. 2017). PDT worked 
through the use of intravenously dosed photosensitizer Verteporfin which was later 
activated by a 689nm red laser. Once activated, the dye forms reactive free radicals that 
cause blood vessels to clot, preventing the further spread (Al-Zamil, W. M., et al. 2017). 
PDT was used worldwide for a brief period, however, due to some unpredictable 
results, PDT led to the recurrence of AMD and the need for multiple retreatments (Al-
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Zamil, W. M., et al. 2017). Following PDT treatment, blood vessels would re-canalize in 
a short time period leading to recurrence and requiring more treatment. Currently, PDT 
is rarely used in treatment of AMD due to expensive cost of equipment and the use of 
more favorable and effective treatments available today.  
 Macugen (Pegaptanib) was the first anti-VEGF drug approved by the FDA in 
2004 for the treatment of wet AMD. Macugen was the first molecular approach used to 
combat the formation of new blood vessels within the eye. Macugen is an RNA aptamer 
that binds specifically to the VEGF-165 isomer with a very high binding affinity. One 
study, VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1), treated 
patients with Macugen (0.3, 1.0, or 3.0 mg intravitreal) every 6 weeks for 48 weeks 
(Gragoudas, E. S., et al. 2004). Following the trial, patients who received the 0.3mg 
treatment remained the same or gained visual acuity compared to the patients who 
received the aptamer control (Gragoudas, E. S., et al. 2004, Al-Zamil, W. M., et al. 2017). 
Since this study, newer and more effective anti-VEGF treatments have come to market, 
have replaced Macugen.  
 Avastin (Bevacizumab) was briefly used off-label in treatment of AMD due to its 
effectiveness over Macugen and its low cost for treatment of eyes (Raftery, J., et al. 
2007). Avastin which is a mouse monoclonal antibody was humanized via site-directed 
mutagenesis of a human antibody framework. This new humanized antibody binds to 
VEGF with the same affinity as the original human antibody (Ferrara, N., et al. 2004). 
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Avastin was designed to be used in the treatments of metastatic colorectal cancer, 
however, the anti-VEGF properties of Avastin was used to help fuel the development of 
Lucentis specifically for patients suffering with AMD. Avastin is still used to treat MAD 
today as an off-label application; due to its low cost.  
  Lucentis (Ranibizumab) was the second anti-VEGF drug that was approved by 
the FDA in 2006 for the treatment of wet AMD. Lucentis is a recombinant humanized 
IgG1 Monoclonal Fab fragment, which can inhibit all biologically active isoforms of 
VEGF-A (Bakri, S. J., et al. 2007).  Lucentis is created using the same parent antibody as 
Bevacizumab (Avastin). Both Lucentis and Avastin work by blocking the binding of 
VEGF which prevents the growth of new blood vessels in the eye. One notable study, 
which funded by The National Eye Institute, Comparison of AMD Treatments Trials 
(CATT), compared Lucentis and Avastin for treatment of wet AMD. Over the 24 month 
course of the trial, there was no difference between the two (Martin, D. F., et al. 2012, 
Kim, B. J., et al. 2014, Al-Zamil, W. M., et al. 2017). Other notable studies suggest a 
difference in effectiveness when comparing Avastin to Lucentis when treating wet 
AMD. Lucentis remains within the eye much longer and therefore fewer treatments of 
intraocular injections would be needed to control the disease (Chakravarthy, U., et al. 
2012).  
The most recent anti-VEGF drug approved by the FDA for the treatment of wet 
AMD is Eylea (Aflibercept). Eylea is a VEGF-A decoy receptor which has a high binding 
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affinity for both VEGF-A and VEGF-B isoforms as well as placental growth factors 
(Browning, D. J., et al. 2012, Stewart, M. W. 2012, Al-Zamil, W. M., et al. 2017). Eylea is a 
recombinant fusion protein made up of the ligand-binding elements of the human 
VEGF receptor 1 and 2, fused to the human immunoglobulin G1 Fc fragment 
(Browning, D. J., et al. 2012, Al-Zamil, W. M., et al. 2017). One notable study, VEGF 
Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW), compared 
treatments of Aflibercept to Ranibizumab (Heier, J. S., et al. 2012). It showed that 
Aflibercept was superior to Ranibizumab (Heier, J. S., et al. 2012, Al-Zamil, W. M., et al. 
2017). The increased effectiveness of Aflibercept is most likely accounted for by its 
higher binding affinity for VEGF when compared to Ranibizumab (Papadopoulos, N., 
et al. 2012).  
 
1.6 Oxidative Stress 
AMD, like many diseases, may be caused by a combination of oxidative stress 
and environmental or genetic factors. Oxidative stress may be defined as an excess of 
reactive oxygen species (ROS) within the cells causing damage to DNA, RNA, protein, 
and lipids. ROS include superoxide anions (O2-), hydrogen peroxide (H2O2) and 
hydroxyl radicals (OH-). Under normal conditions, ROS molecules are commonly used 
as a defense mechanism in the body against bacteria and other pathogens (Simon, H. U., 
et al. 2000). Chronic inflammation and excess ROS within cells have been shown to lead 
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to tissue damage and ultimately cell death (Ray, P. D., et al. 2012; Khaper, N., et al, 
2010). Antioxidant enzymes within the body help to control ROS within the body 
namely: superoxide dismutase, catalase, and glutathione peroxidase (Poljsak, B., et al. 
2014). These enzymes convert ROS molecules into unreactive or inert molecules that the 
body can metabolize. Superoxide dismutase (SOD) converts superoxide (O2-) radical 
into oxygen (O2) and hydrogen peroxide (H2O2) (Oberley, L. W., et al. 1979). Catalase in 
turn transforms H2O2 into water and oxygen (Aebi, H. 1974). Glutathione peroxidase 
reduces H2O2 and lipid peroxides into water and lipid alcohols. These in turn can be 
removed from the body (Wendel, A. 1981). If the concentrations of these enzymes are 
insufficient to breakdown ROS, excess ROS ultimately leads to cell damage and cell 
death. Overproduction of ROS within cells can lead to lipid peroxidation (Zhong, H., et 
al. 2015). Lipid peroxidation can be measured through the lipid peroxidation byproduct 
4-hydroxynonenal (4HNE)  (Zhong, H., et al. 2015). Figure 1.5 illustrates how the 






Figure 1.5: The Oxidative Stress Response. Negative effects of oxidative stress are 
counteracted in the body by naturally occurring antioxidants MnSOD, and catalase. 
These antioxidants convert ROS into unreactive or inert molecules the body can 
metabolize. Caspase-3 plays a crucial role in apoptosis signaling during oxidative stress. 
4HNE is an indicator of lipid peroxidation. 
 
1.7 Antioxidants  
Antioxidants are produced naturally within the body; however, antioxidants can 
also be taken as supplements in order to boost the body’s natural defense to these 
molecules. Antioxidants are substances that slow down the damage caused by free 
radicals (Halliwell, B. 1996). A common antioxidant is Vitamin C. Natural antioxidants 
are found commonly in plants and fruits. These can be categorized into flavonoids, 
tannins, phenols and lignans. Antioxidants can act in many different ways within the 
body. They can function to attenuate inflammation, enzyme inhibition and inhibit cell 
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proliferation. Antioxidants have the potential to slow down aging within cells and do 
this by working together with the intracellular reductant network (Rice-Evans, C. 2001). 
The chemical structure ultimately determines the metabolism and uptake for each 
antioxidant. (Rice-Evans, C. 2001).  
 
1.8 Stilbenes 
Naturally occurring bi-phenol compounds in plants are one of many biologically 
active polyphenolic compounds produced by plants. Stilbenes are of small molecular 
weight and are naturally occurring compounds produced by plants. They are 
commonly used in aromatherapy products and dietary supplements (Roupe, K. A., et 
al. 2006). In plants, stilbenes are produced as a defense mechanism to environmental 
threats like parasite infestation, fungal infection, or excessive UV exposure (Roupe, K. 
A., et al. 2006).  Stilbenes exist in both trans- and cis- isomers, however, in nature the 
trans- isomer is more biologically active (Roupe, K. A., et al. 2006). Stilbenes are known 
for their strong antioxidant and therapeutic properties, two commonly studied stilbenes 
are resveratrol and pterostilbene (Shen, T., et al. 2009). Figure 1.6 shows the structures 
of isomers of both resveratrol and pterostilbene (Shin, H. J., et al. 2020).  
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Figure 1.6. Molecular structures of resveratrol and pterostilbene. Trans-resveratrol 
(trans-3,5,4’ trihydroxy- stilbene) has three hydroxy groups and a molecular weight of 
228.25g/mol, whereas Trans-pterostilbene (trans-3,5-dimethoxy-4’-hydroxystilbene) has 
two methoxy groups and one hydroxy group and a molecular weight of 256.29g/mol. 
Both compounds have Trans- and Cis- isomers. 
 
1.9 Resveratrol 
Resveratrol (trans-3, 5, 4’trihydroxy- stilbene) is a polyphenol produced by a variety of 
plants in response to injury or fungal attack (Frémont, L. 2000). It was first identified in 
the 1940s from the roots of the White Hellebore (Takaoka, M. 1940, Silva, P., et al. 2019) 
and shortly after in large quantities in Japanese Knotweed (Nonomura, S., et al. 1963, 
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Silva, P., et al. 2019). In Japanese and Chinese traditional medicine, resveratrol is used to 
treat conditions like skin inflammation, fungal diseases, and diseases of the heart, liver, 
and blood vessels (Bradamante, S., et al. 2004). Resveratrol exists in both cis- and trans- 
isomers, however the trans- isomer is most commonly studied due to its prevalence in 
nature and its biological activity (Frémont, L. 2000, Burns, J., et al. 2002). Resveratrol is 
found specifically in the skins of some fruits such as grapes, blueberries, mulberries, 
cranberries, as well as certain teas (Frémont, L. 2000, Burns, J., et al. 2002, Wenzel, E., et 
al.  2005). Grapes, specifically grape skin, has a very high concentration of resveratrol 
and red wine has been noted to be the most concentrated food source for resveratrol in 
the human diet (Silva, P., et al. 2019).  
Resveratrol is found in high concentrations in red wine and low concentrations 
in white wine, the overall concentration will range depending on a variety of factors 
including type of grape, geographic origin, type of wine, and growth practices 
(Frémont, L. 2000). The concentration of resveratrol in wine is mostly determined by the 
fermentation time with grape skins (Jeandet, P., et al. 1991, Frémont, L. 2000). Higher 
concentrations of resveratrol are therefore found in red wine as opposed to white wine 
due, to longer fermentation time.  
Resveratrol has a variety of therapeutic properties including antioxidative, 
anticarcinogenic, cardioprotective, anti-inflammatory, and anti-aging (Burns, J., et al. 
2002, Baur, J. A., et al. 2006).  Tamaki, N., et al. (2014), hypothesized that resveratrol 
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reduces oxidative stress through the sirtuin 1 (SIRT1), AMP-activated protein kinase 
(AMPK), and nuclear factor E2-related factor 2 (NRF2) defense pathways.  Upon 
activation of these pathways, an increased level of resistance to oxidative stress and 
protection against inflammation takes place (Tamaki, N., et al. 2014). Resveratrol in red 
wine has been suspected to be a cardio-protective nutritional supplement. Resveratrol 
can provide protection to the cells of the cardiac muscle by minimizing cardiomyocyte 
apoptosis (Vidavalur, R., et al.  2006). Kalantari, H., et al. (2010) have extensively 
reviewed the many beneficial physiological effects of resveratrol and their results can be 












Table 1.1 Therapeutic Uses of resveratrol. Highlighted findings from the review 
conducted by Kalantari, H., et al. 2010. 
Property Summary of Relevant Information 
Anti-oxidative 
• Resveratrol can scavenge free radicals (antioxidant properties) due 
to its favorable structure.  
• in vitro- Indicate RES is poor antioxidant properties  
• in vivo- Indicates potent antioxidant properties  
Cellular Protection • Protection of heart, brain, and kidney cells 
• Increases Apoptosis and reduces tumor growth  
Anti-carcinogenic 
• Resveratrol blocks the multistep process of carcinogenesis at 
various stages: it blocks carcinogen activation by inhibiting aryl 
hydrocarbon-induced CYP1A1 expression and activity, and 
suppresses tumor initiation, promotion and progression. 
Cardioprotective 
• Resveratrol can be used as a treatment for various cardiovascular 
disorders; myocardial ischemia reperfusion injury, congestive 
heart failure, coronary arterial atherosclerosis, and chemically 
induced cardiotoxicity. 
Anti-inflammatory 
• Protection of cardiovascular muscle comes from its ability to 
minimize inflammation. 
• Suppressed aberrant expression of tissue factor and cytokines in 
vascular cells.  
Anti-aging 
• A 2006 study showing resveratrol made mice live longer when 
given resveratrol supplements. 
• Tests on RPE cells show that resveratrol can reduce oxidative 
stress and hyperproliferation of RPE.   
• resveratrol generates a survival signal by inducing activation of 
Akt, and inhibiting P38MAPK as well as increasing DNA binding 
of NF-kB.  
• Mechanism is not fully known, suggestions that resveratrol 







1.10 Resveratrol and AMD  
 
Resveratrol has been studied in ARPE-19 cells for its protective ability in damage 
caused by H2O2. King, R. E., et al. (2005) showed that 50µM and 100µM treatments of 
resveratrol were able to significantly reduce the proliferation of ARPE-19 cells by 10% 
for 50µM treatments and 25% for 100µM treatments. From their studies, resveratrol was 
also able to inhibit the H2O2-induced cellular oxidation and provide protection for 
ARPE-19 cells (King, R. E., et al. 2005). These results suggest that in diseases like AMD 
where oxidative stress is thought to be a strong contributing factor, resveratrol may be 
used as a treatment in reducing oxidative stress and minimizing the progression of 
AMD. Two notable studies AREDS and AREDS 2 (Age Relates Eye Disorder Studies) 
recently illustrated promising results that dietary supplements were able to slow down 
the progression of AMD (Chew, E. Y., et al. 2012).  
Resveratrol has been studied to investigate its effects on VEGF expression for 
cancers and other diseases. Numerous studies have shown that resveratrol has a 
regulatory negative effect on angiogenesis in many diseases including cancer (Khan, A. 
A., et al. 2010, Cullberg, K. B., et al. 2013, Wu, H., et al.2018). Studies showing 
resveratrol mediated reduction of angiogenesis suggests that this is caused by overall 
reduction in glycolysis. This may be mediated by the PI3K/Akt and mTOR signaling 
pathways (Faber, A. C., et al. 2006, Wu, H., et al.2018). Although the mechanism for 
inhibition of angiogenesis is not fully understood, it is thought resveratrol would be a 
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possible means to treat diseases directly involved with VEGF, such as wet AMD with 
angiogenesis.  
 
1.11 Pterostilbene  
  Pterostilbene (trans-3,5-dimethoxy-4’-hydroxystilbene) is a naturally occurring 
di-methylated derivative of resveratrol primarily found in blueberries (Roupe, K. A., et 
al. 2006, McFadden, D. 2013). The concentration of pterostilbene in blueberries is 
dependent on the species and origin but generally ranges from 99ng/gram to 
520ng/gram of fruit (McFadden, D. 2013). Pterostilbene has been well studied and has 
shown promising results as a strong antioxidant (McFadden, D. 2013, Li, Y. R., et al. 
2018), protectant against cardiovascular disease (Li, Y. R., et al. 2018), and many types of 
cancer (McCormack, D., et al. 2012).  
Although pterostilbene’s mechanism of action in treating many of these diseases 
is not fully understood, it is suggested that ROS plays a strong role (McFadden, D. 
2013). Pterostilbene is able to increase the antioxidant concentrations to help fight 
diseases where ROS is involved, and it is also able to induce cell apoptosis in various 
types of cancers (McFadden, D. 2013). A recent animal study has suggested that 
pterostilbene has a much higher bioavailability at 80% compared to resveratrol at 20% 
(McCormack, D., et al. 2012).  Pterostilbene may have higher bioavailability in 
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mammals than resveratrol due to the addition of two methyl groups (Figure 1.6) which 
improves its lipophilic nature and oral absorption (McCormack, D., et al. 2012).  
In an animal study by Wang, B., et al. (2016), pterostilbene showed significant 
results when used to minimize oxidative stress in the brains of mice. Along with 
minimizing oxidative stress, pterostilbene was able to reduce neuronal cell apoptosis 
(Wang, B., et al. 2016). These results indicate strong antioxidant capacity and suggest 
promising results when investigating diseases where oxidative stress plays a role. 
Therefore, pterostilbene, like resveratrol, may be an important player in the treatment of 
AMD due to its ability to scavenge ROS and reduce overall cellular oxidative stress.   
 
1.12 Blue Light 
  Excessive blue light can lead to the accumulation of oxidants and ultimately lead 
to cell death and vision loss. A study by Taylor, H. R., et al. (1990) has shown that blue 
light can cause cellular damage within the eye similar to those seen in patients with 
AMD. Blue light is a growing concern in our everyday lives, due to the number of hours 
we spend in front of screens, and is characterized by the 400 to 495nm wavelengths on 
the visible light spectrum. The short wavelength increases the ability to penetrate to the 
eye, leading to damage to the RPE layer (Taylor, H. R., et al. 1990). The retina is at risk 
for oxidative stress as it has a high proportion of polyunsaturated fatty acids, high 
oxygen consumption, and chronic exposure to visible and ultraviolet light spectrums.  
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In an animal study by Wielgus, A. R., et al. (2010) rats were exposed to 450nm 
blue light for 6 hours. In the blue light-exposed rats, it was found that there was a much 
higher concentration of N-retinyl-N-retinylidene ethanolamine (A2E) oxidization 
within the cells. This oxidized form of A2E, a metabolic waste which is toxic to the 
retinas and was found in high concentrations in the rats that were exposed to blue light. 
This study suggests that there is a strong link between exposure to blue light and retinal 
injury (Wielgus, A. R., et al. 2010).  
Blue light has been studied in cell lines, specifically ARPE-19 cells. ARPE-19 is a 
spontaneously arising RPE cell line derived in 1986 from the normal eyes of a 19-year-
old male who died from head trauma in a motor vehicle accident (ATCC 2020). 
Brandstetter, C., et al. (2015) showed that exposing cells to blue light caused significant 
damage to ARPE-19 cells and increased apoptosis. Marshall, J. C. A., et al. (2006) 
showed that exposing human uveal melanoma cells to 3 hours of blue light per day for 
4 days increased the proliferation of cells when compared to control cells that were not 
exposed to any blue light.  
Blue light exposure, smoking, and high fat diets all play crucial roles in the 
progression of AMD. In AMD, Retinal Pigment Epithelial (RPE) cells are directly 
involved with the deterioration of vision as the disease progresses. In both wet and dry 
AMD, it is believed that ROS is a key player in the origin and progression of AMD. 
Although resveratrol and pterostilbene have shown promising results in studies 
 35 
relating to AMD and across many other areas of research (ie. anti-cancer, anti-aging, 
and anti-tumor), their precise mechanism of action is not fully understood. This study 
explores the potential benefits of resveratrol and pterostilbene as nutritional 
supplements in patients with AMD. This will be accomplished through the use of in 
vitro studies involving retinal cell exposed to blue light with reproducible conditions in 
















Chapter 2: Rationale 
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2.1 Rationale  
 
Age-related macular degeneration (AMD) is a common progressive eye 
condition that is the leading cause of visual impairment in adults over the age of 50 
worldwide (Moutray, T. et al. 2011).  AMD is characterized by acute or chronic vision 
loss (Jager, R. D. et al.2008).  
 In AMD, RPE cells are directly involved with the deterioration of vision as the 
disease progresses. In both wet and dry AMD, it is believed that ROS is a key player in 
the origin and progression of AMD. Although resveratrol and pterostilbene have shown 
promising results in studies relating to AMD and across many other areas of research 
(ie. anti-cancer, anti-aging, anti-tumor), their mechanism is not fully understood. This 
study is a primary step in understanding resveratrol and pterostilbene and possible 
beneficial effects in patients with AMD. This will be accomplished through the use of in 
vitro studies with reproducible conditions.  
 
2.2 Hypothesis 
Resveratrol and pterostilbene, due to their similar structure and strong 
antioxidant capacity, will attenuates oxidative stress-mediated damage in cells exposed 
to blue light by upregulating the endogenous antioxidants.  
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2.3 Specific Aims 
1.    Optimize the cell culture model of blue light exposure to ARPE-19 cells.  
2.    Determine the effects of resveratrol and pterostilbene on cell proliferation. 
3.    Investigate the effects of resveratrol and pterostilbene on oxidative stress and cell 
death in ARPE cells exposed to blue light.  
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Chapter 3: Methods 
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3.1 Cell Culture Methods 
Human retinal pigment epithelial (RPE) cell line, ARPE-19, were obtained from 
the American Type Culture Collection (Manassas, VA, USA). ARPE-19 cells were grown 
in T-75 or T-25 culture flasks (Sigma-Aldrich, St. Louis, MO, USA) with Dulbecco’s 
Modified Eagle’s Medium F12 supplemented with 15 mM HEPES and sodium 
bicarbonate (DMEM:F12) (Sigma-Aldrich, St. Louis, MO), 5% fetal bovine serum (FBS) 
(GE Health Care, Canada) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, 
USA). At first, ARPE-19 cells were grown to 80% confluency and 70% of cells were 
frozen under liquid nitrogen. These were defined as passage 1 or 2. A single vial of 
passage 1 or 2 cells was used to start each set of experiments. All ARPE-19 cells were 
cultured at 37°C with 5% CO2 and grown to approximately 95% confluency prior to 
splitting or performing experiments. All experiments were performed within 15 
passages of each other between passage 3 and passage 18.  
 
3.2 Preparation of Resveratrol and Pterostilbene Stock Solutions   
Resveratrol (Millipore Sigma, Oakville, ON, CA) 5mM stock solution was 
prepared in distilled water. Varying concentrations of resveratrol were prepared by 
diluting 5mM stock solutions into serum and antibiotic-free DMEM:F12 media.  
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Pterostilbene (TCI America, Portland, OR, USA) 5mM stock solution was 
prepared in dimethylsulfoxide (DMSO). Different concentrations of pterostilbene were 
prepared by diluting 5mM stock solutions into serum and antibiotic-free DMEM:F12 
media. Final dilutions of pterostilbene which were added to the cells were created in a 
way that the concentration of DMSO was less than 1%.  
Cells treated with resveratrol or pterostilbene were incubated at standard cell 
culture conditions for 12 hours. For experiments using pterostilbene, appropriate 
controls were carried out with dilutions of DMSO (vehicle control).  
 
3.3 Preparation of ARPE-19 Cells for Each Experiment 
ARPE-19 cells were seeded with DMEM:F12 into two 96 well plates with 5x105 
cells per well.  Cells were then left undisturbed for 24 hours in order to allow them to 
adhere to the plate. Cells were grown in supplemented media along with the addition 
of various concentrations of treatment. Control wells not receiving any special 
treatment were given matching volumes of supplemented media to ensure identical 
volumes. The outer edge of the 96-well plate was not used due to uncontrolled 




3.3.1 Resveratrol Treatment 
  5mM stock concentrations of resveratrol was diluted to 2.5mM with DMEM:F12 
media. Appropriate amounts of freshly diluted stock solutions were added to each 
treatment well. Vehicle control (DMSO) and positive control (300µM hydrogen 
peroxide) were also added to designated wells on each plate. Following the addition of 
resveratrol, each plate was placed in an incubator at standard conditions, for 4 hours 
prior to the addition of blue light. One plate was then subjected to blue light treatment, 
while the identical plate was kept in the dark under the same conditions.  
 
3.3.2 Pterostilbene Treatment 
5mM stock concentrations of pterostilbene was diluted 500µM with DMEM:F12 
media. Appropriate amounts of freshly diluted stock solution were added to each 
treatment well. Vehicle control (DMSO) and positive control (300µM hydrogen 
peroxide) were also added to designated wells on each plate. Hydrogen peroxide was 
chosen as a positive control due to its use as a standard oxidant in cell culture models.  
Following the addition of each treatment, each plate was placed in an incubator at 
standard conditions, for 4 hours prior to the addition of blue light. One plate was then 
subjected to blue light treatment, while the identical plate was kept in the dark under 
the same conditions.  
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3.4 Blue Light Exposure  
ARPE-19 cells were exposed to blue light under standard incubation conditions 
for 12 hours. Blue light was delivered by a specifically designed LED manifold with 72 
blue LED’s calibrated to a wavelength of 470nm (Figure 3.2). The LEDs were soldered to 
a PCB board in a series of 6 LEDs with a 150-ohm resistor. 12 rows of the LED resistor 
combinations were connected in parallel and connected to a power supply giving 24.8 
volts per panel to ensure each LED received sufficient power at the correct spectra. The 
LED panel was supported on top of the 96-well plate with a custom-designed support 
that held the panel 6 cm from the top of the 96-well plate. Exposure to blue light was 
carefully monitored using a mechanical timer in order to ensure all exposure times were 
identical.  
Figure 3.1 Blue Light Manifold on T-25 Flask. The blue light manifold supported on 
top of a T-25 flask to show how it is used in the tissue culture incubator. The LED panel 
is connected to a power supply and mechanical timer. These work together to ensure 
that the LED panel receives the required voltage of power for the proper duration of 
time.  
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3.5 Cell Viability Assay  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
originally used to measure cell viability. Measurements were made following the 
manufacturer’s protocol. In brief, 5x105 cells were plated into 96-well plates and allowed 
24 hours to adhere and stabilize. After 24 hours, viability experiments were initiated by 
adding the desired concentration of treatment for 4 hours followed by the appropriate 
12-hour exposure to blue light. Following the blue light exposure, 20µL of MTT reagent 
was added directly to each well and incubated for 4 hours. Following incubation, media 
was aspirated from the wells and 50µL of DMSO was added. The plate was covered 
with tinfoil and placed on a shaker for 10 minutes. Following shaking, the absorbance 
was read using a BioTek Cytation 5 96-well plate reader (BioTek, Winooski, VT, USA) at 
490 and 650nm. Difference in absorbance was used as a quantitative assessment of 
viability.  
Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies, Inc, USA) was 
used to assess cell viability. Measurements were made following the manufacturer’s 
protocol. In brief, 5x105 cells were plated into 96-well plates and allowed 24 hours to 
adhere and stabilize. After 24 hours, viability experiments were initiated by adding the 
desired concentration of treatment for 4 hours followed by the appropriate 12-hour 
exposure to blue light. Following the blue light exposure, 10µL of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
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(MTS) reagent was added directly to each well and incubated for 4 hours. The 
absorbance was then read using a BioTek Cytation 5 96-well plate reader (BioTek, 
Winooski, VT, USA) at 450nm. Background absorbance was subtracted using a set of 
wells that contained media and MTS reagent. Values were expressed as a relative 
percentage of the controls.  
 
3.6 Caspase 3/7 Fluorescence Assay  
  CellEvent Caspase 3/7 Green Detection Reagent (Invitrogen, Carlsbad, CA, USA) 
was used to investigate the activation of caspase-3 during apoptosis. Measurements 
were made and images were collected following the manufacturer’s protocol. The 
CellEvent Caspase 3/7 Green Detection Reagent was diluted to 2µM in PBS with 5% 
FBS. Treatment media was aspirated from the wells and 100µL of the diluted reagent 
solution was added. The cells were incubated with the reagent for 30 minutes prior to 
imaging and reading fluorescence at 502nm/530nm excitation/emission maxima 
respectively using a BioTek Cytation 5 96-well plate reader with Gen5 version 3.06 
(BioTek, Winooski, VT, USA ).  Imaging was conducted using the 465nm LED cube for 
the Cytation 5 plate reader in imaging mode. Images were analyzed using the Gen5 
Image analysis software and the mean value of fluorescence at 530nm was measured in 
each well.  
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3.7 Preparation of Total Cellular Protein Lysate  
In order to collect sufficient quantities of total cellular protein, ARPE-19 cells 
were seeded in T-25 flasks at a 1:3 ratio. ARPE-19 cells were treated with resveratrol and 
pterostilbene under both control (darkness) and treatment (blue light exposure) 
conditions for 12 hours prior to cell collection using trypsinization.  Cells were 
subjected to centrifugation at 500xg for 5 minutes and the cell pellets were washed 
twice with PBS. Protein was extracted from the cell pellet using mechanical disruption 
with a lysis buffer containing 25mM Tris (pH 7.5), 150mM NaCl, 1% Triton X-100, 2mM 
EDTA, 1% protease inhibitor cocktail, 1% sodium orthovanadate, and 4% sodium 
fluoride. Lysis was performed using a sterile Qiagen 5mm stainless-steel bead (Qiagen, 
Toronto, ON, CA) then homogenized using the Qiagen TissueLyser (Qiagen, Toronto, 
ON, CA) run at 20Hz for 3 minutes. The bead was removed. The samples were then 
centrifuged at 20000xg for 15 minutes and supernatant transferred to a new tube for 
storage at -80°C. The concentration of protein in stored cellular lysates was quantified 






3.8 Western Blot Analysis   
Cellular lysates were diluted to a final concentration of 1µg/µL using dH2O and 
4x SDS reducing loading dye. 30µg of each protein was loaded into an SDS-PAGE gel 
(7-15% dependent on the size of the protein of interest) and subjected to electrophoresis. 
Following completion, the gel was transferred to a nitrocellulose membrane (GE 
Healthcare, CA) electrophoretically using a Trans-Blot apparatus (Bio-Rad Laboratories, 
Mississauga, ON, CA). The membrane was blocked using 5% nonfat milk in Tris-
buffered saline (TBS) (20mM Tris, 137mM NaCl) for 1 hour at room temperature. 
Following blocking, membranes were incubated overnight at 4°C with the following 
antibodies: 4-HNE (1:1000) (Cell Signaling, CA), Caspase 3/7 (1:1000) (Cell Signaling, 
CA), catalase (1:1000) (Abcam, USA), and MnSOD (1:1000) (Millipore, CA). Membranes 
were washed using 1xTBST then incubated for two hours using an anti-rabbit 
secondary antibody (1:1000) (R&D Systems, USA) at room temperature.  
Following incubation, membranes were again washed and proteins if interest were 
visualized by enhanced chemiluminescence (ECL). ECL was performed to detect 
protein banding patterns on immunoblot membranes by horseradish peroxidase-
conjugated to secondary antibodies. ECL solution was made fresh every time. 
Membranes were washed in ECL solution for 5 minutes prior to detection. 
Chemiluminescent immunoblots were detected by using Chemidoc imager (Bio-Rad 
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Laboratories, Mississauga, ON, CA) in protein gel mode. Figure 3.2 summarizes the 
major steps used in visualizing proteins through a western blot.  
 
Figure 3.2 Summary of Western Blot Protocol. Visualization of cellular protein was 
performed utilizing western blots as described above.  
 
3.9 Necrosis Assay 
To ensure adequate cell density, ARPE-19 cells were seeded in a 6-well plate 
prior to treatment. Following treatment and exposure to blue light, cells were removed 
by trypsinization and collected by centrifugation at 500xg for 5 minutes. The cellular 
pellets were washed twice using 1x PBS. Finally, the cells were resuspended in 400µL of 
PBS, followed by the addition of 2µL of Propidium Iodide (PI) solution (Sigma-Aldrich, 
Oakville, ON, Canada). ARPE-19 cells that received no compound were used as a 
control from both the dark plate and the blue light exposed plate, H2O2 was used as a 
positive control. The percentage of positive (apoptotic) cells was determined using flow 




Figure 3.3 summarizes the major assays preparation for all the various 
experiments performed in this project.  
 
Figure 3.3 Treatment Summary ARPE-19 cells were plated in either 96-well, 6-well, or 
T-25 culture vessels as indicated and allowed to adhere for 24 hours. They then received 
4 hours of pre-treatment of either resveratrol or pterostilbene. After 4 hours, the blue 
light was turned on and allowed the cells were exposed for 12 hours. Subsequently, 
assays were carried out as described in the methods section and as shown in the figure.  
 
3.10 Statistical Analysis  
The optimized data corresponds to four (n=4) independent experiments with the 
exception of the western blots (n=1). All statistical analyses were performed using 
Graph Pad Prism 8 software (GraphPad Software, San Diego, CA, USA). Data was 
presented as mean ± standard error of the mean (SEM). All data used one-way 
ANOVAs with Tukey’s post-hoc test with p ≤0.05 indicating significance.  
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Chapter 4: Results 
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4.1 Optimization  
 Prior to testing the effects of blue light, resveratrol, and pterostilbene on ARPE-
19 cells, the experimental system needed to be optimized. The variables to be 
considered were concentration of the compounds (resveratrol and pterostilbene), 
duration of pre-treatment, duration of treatment, and duration of blue light exposure. 
Due to a paucity of detailed information in previous literature, it was essential to create 
an experimental system that was reproducible. Moreover, due to conflicting results in 
previous studies, the dose-dependent effects of resveratrol and pterostilbene on ARPE-
19 cells needed to be determined. Figure 4.1 shows the parameters that were optimized 





Figure 4.1. Optimization Steps. This figure outlines the major steps of optimization that 



























4.2 Compound Optimization  
4.2.1 Compound Optimization – resveratrol  
To test the dose-dependent effects of resveratrol on ARPE-19 cells, cells were 
plated at 3x104 cells per well in a 96-well plate. Treatments of 50µM, 100µM, and 200µM 
of resveratrol were added to appropriate wells. Following treatment, cell viability 
assays were performed and values were plotted on a bar graph verses control cells 
which received no treatment at all. Figure 4.2 represents the results from the 
optimization of resveratrol. Results from the viability assay of 50µM, 100µM, and 
200µM of resveratrol after 12 hours of treatment showed that all three concentrations 
had significant reductions (p<0.050) in cell viability on ARPE-19 cells. A slight reduction 
of cell viability was expected on control untreated  cells in culture due to a lack of ROS 
present. However, resveratrol concentrations of 50µM and 100µM were selected for 







Figure 4.2. Resveratrol optimization. Effects of resveratrol alone on ARPE-19 cells. 
Cells were treated with 50µM, 100µM, and 200µM of resveratrol for 12 hours before 
media was removed and MTT reagent was added. Absorbance values were obtained 
using a BioTek Plate reader using KC4 acquisition software. (n=7, * denotes significant 






















4.2.2 Compound Optimization – pterostilbene 
To test the dose-dependent effects of pterostilbene on ARPE-19 cells, cells were 
plated at 3x104 cells per well in a 96-well plate. Treatments of 10µM, 25µM, 50µM, 
75µM, 100µM, and 125µM of pterostilbene was added to appropriate wells. Following 
treatment, cell viability assay were performed and values were plotted on a bar graph. 
Figure 4.3 represents the results from the optimization of pterostilbene. Results from the 
viability assay of 10µM, 25µM, 50µM, 75µM, 100µM, and 125µM of pterostilbene after 
12 hours of treatment showed that all concentrations, with the exception of 10µM and 
125µM, showed a significant increase (p<0.050) in cell proliferation. Following these 
results, 10µM and 25µM concentrations of pterostilbene were used in all future 
experiments. These were selected to conform with amounts used in previous studies, 
and to account for the higher bioavailability of pterostilbene when compared to 





Figure 4.3. Pterostilbene optimization. Effects of pterostilbene alone on ARPE-19 cells. 
Cells were treated with 10µM, 25µM, 50µM, 75µM, 100µM, and 125µM for 12 hours 
before media was removed and MTT reagent was added. Absorbance values were 
obtained using a BioTek Plate reader using KC4 acquisition software. (n=4, * denotes 






















4.3 Blue Light Optimization  
There is a lack of detailed information on in previous studies on exposing cells to 
blue light. It was important to design a blue light device that was able to not only 
provide reproducible results but also be able to be employed in a tissue culture 
incubator at 37°C and 5% CO2 injection. The prototype of the blue light apparatus is 
shown in Figure 4.4. This apparatus consisted of a small breadboard with 12 LED lights 
connected to a 9-volt battery. The LED lights were then supported on top of a 96-well 
plate using a specially designed hood which was 3D printed out of ABS plastic to be the 
match the plate. Using this manifold, exact placement over the wells was possible. 
  
Figure 4.4 A&B. Blue Light Apparatus 1. A: Twelve LED’s connected on a breadboard 
to 9 volts of power. B: LED panel supported on top of a 96-well plate in the tissue 





We discovered, upon testing that the first Blue light apparatus prototype had 
problems due to the battery power supply. There was the possibility of voltage drop 
from the 9-volt battery over the course of the exposure time. As the voltage to the LED 
dropped, the intensity of light would reduce therefore altering exposure to blue light 
over the course of the experiment. Overall duration of full intensity would also be 
dependent on the starting capacity of the battery, storage conditions, and brand of 
battery. A 9-volt power supply therefore used to provide constant power. The power 
supply was also placed outside the tissue culture incubator to prevent the exposure of 
cells to excess radiant heat. By connecting the power supply outside the incubator, any 
radiant heat generated from the device would not affect the temperature within the 
tissue culture incubator.  
To test the effects of blue light on ARPE-19 cells, cells were plated at 3x104 cells 
per well in a 96-well plate and allowed to adhere for 24 hours. Following adherence, the 
blue light apparatus was placed on top of the 96-well plate and turned on for 24 hours. 
Following the blue light treatment, media was removed and cell viability assays were 
performed using MTT assay. Values were plotted on a bar graph. Control cells in a 
second plate which received no light treatment at all. Figure 4.5 represents the results 






Figure 4.5. Blue Light Optimization. Effects of blue light alone on ARPE-19 cells. Cells 
were treated with blue light for 24 hours before media was removed and MTT reagent 
was added. Absorbance values were obtained using a BioTek Plate reader using KC4 
acquisition software. (n=3) 
 
 This experiment showed blue light exposure reduced viability of the cells. At this 
juncture a second prototype was built which would allow an entire 96 well plate to be 
tested with blue light. This would allow for twice as many treatment conditions to be 
conducted at once. By adding the second LED panel the voltage from the power supply 
was doubled to maintain the same intensity. A second blue light exposure experiment 
was then performed to ensure similar results were seen. The new dual-panel blue light 
apparatus was placed on top of the 96-well plate and turned on for 24 hours. Results 
from this assay illustrated that all the cells that were exposed to 24 hours of blue light 
were dead. These results were unexpected as the second experiment was performed in 
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the same manner as the first, with the additional blue light panel being the only 
alteration to the manifold.  
 A third experiment was performed, reducing the blue light exposure time to 12 
hours to determine if this made a difference on the amount of cells that survived. The 
dual-panel blue light apparatus was placed on top of the 96-well plate and turned on 
for 12 hours. Results from this MTT assay showed that all the cells exposed to 12 hours 
of blue light were also dead. We expected cells that were exposed for a shorter duration 
would be more viable, however this was not the case.  
 A benchtop experiment was performed with a lab grade fridge/freezer 
thermometer that was placed under the blue light apparatus where maximum and 
minimum values were reset. The lights were left on for 12 hours and the temperature 
was monitored over the course of the experiment. From this benchtop experiment, we 
determined that the temperature (at the cell level) increased by 15°C. At this juncture, 
we concluded that the heat from the blue light manifold might be killing the cells. The 
increase in temperature was caused by an increase in voltage, due to the additional LED 
panel. Another attempt to vacate some of the air from around the cells during treatment 
the LED panels, by suspending the breadboards and LEDs above the plate, failed and 
the cells completely died. Following this discovery, a second prototype of the blue light 
device was created.  
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 The second prototype consists of a high-quality fiberglass printed circuit board 
(PCB) that has 72 LED’s soldered in parallel. In order to ensure the LEDs did not get too 
much voltage and prematurely burn out, 150 Ohm resistors were added. These LEDs 
and resistor combinations were then soldered onto the computer board and connected 
in series with a positive and negative lead, which was then connected to a high-quality 
power supply with an adjustable voltage output. The voltage that was calculated based 
on the LED manufacturer’s guidelines to ensure a desired output wavelength of 470nm.  
The LED panel was supported on top of the 96-well tissue culture plate by machine 
screws and nuts that allowed the panel to be suspended at the same height as the first 
prototype, but also to ensure that no air was trapped on top or around the culture plate. 
The second prototype of the blue light apparatus is shown in Figure 4.6.  
 
Figure 4.6 A,B,&C. Blue Light Apparatus 2. A: 72 LED’s connected on a computer 
board with power leads to supply 22.5 volts of power. B: LED panel supported on top 
of a tissue culture flask to show how the open sides allow for constant airflow around 
the tissue culture vessel in the tissue culture incubator. C: Wiring schematic that was 
designed to allow for 12 rows of 6 LED’s to ensure full coverage of the tissue culture 
vessel below.  
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 Following the completion of the second prototype, an analysis of temperature 
change was carried out. The benchtop temperature test showed no change in 
temperature over the course of 12 hours. Cells were exposed to blue light for 12 hours 
using the second prototype. Results from this exposure can be seen in Figure 4.7. This 
showed a 56% reduction in viable cells after exposure to blue light.  
Figure 4.7. Blue Light Optimization for prototype 2. Effects of blue light alone on 
ARPE-19 cells. Cells were treated with blue light for 12 hours before media was 
removed and MTT reagent was added. Absorbance values were obtained using a 
BioTek Plate reader using KC4 acquisition software. **p<0.0001 
 
These tests confirmed that the second prototype of the blue light apparatus 
worked well on cells and could be used for future experiments. A second blue light 
manifold was constructed to allow twice as many tissue culture vessels to be exposed to 
blue light at once. Further tests showed that the two units of the second prototype were 
identical. 
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4.4 Assay Optimization 
 At the start of the project, the MTT assay was used as a method of measuring cell 
viability. The MTT assay was compared to the more modern MTS assay and showed 
different results. We suspected that the results from the MTT assay were different that 
the MTS assay due to the removal of media post treatment. When removing media with 
vacuum, any cells that may be dead or dying might be removed from the bottom of the 
vessel unexpectedly. The small size of the wells on a 96-well plate may actually 
emphasize the pressure the cells are experiencing and cause even more to dislodge. The 
MTT assay was therefore phased out and all further experiments were conducted using 
the MTS assay other studies have suggested it is the more superior method of 
measuring cell viability due to its one step simplicity with no removal of media.  
 
4.5 Optimized Results 
 
4.5.1 MTS Assay: resveratrol, pterostilbene and Blue Light  
The MTS assay was used to measure cell viability across different treatments on 
ARPE-19 cells. Resveratrol 50 & 100µM and pterostilbene 10 & 25µM was added to 
appropriate wells. Cells were pre-incubated with resveratrol and pterostilbene for 4 
hours before the blue light apparatus was turned on and cells were exposed to blue 
light for 12 hours. Figure 4.8 represent the results from the MTS assay testing the 
protective role of resveratrol and pterostilbene on ARPE-19 cells exposed to blue light 
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for 12 hours. Resveratrol (50µM) significantly maintained cell viability by 37% when 
compared to control cells exposed to blue light. H2O2 was used as a positive control for 
both control and blue light treatments. Pterostilbene showed no significant changes in 
cell viability for either condition, rather, the number of viable cells when treated with 
25µM of pterostilbene was less than the control.  
 
Figure 4.8. MTS Assay. Cell Viability using MTS assay. Cells were pre-treated for 4 
hours with resveratrol 50µM & 100µM and pterostilbene 10µM & 25µM, followed by 12 
hours of exposure to either blue light or kept in the dark. MTS reagent was used to 












4.5.2 Caspase 3/7 Fluorescence Assay: resveratrol, pterostilbene and Blue Light  
 
Caspase 3/7 is an important protein which is produced during cellular apoptosis. 
It was expected that cells exposed to blue light would have a higher fluorescence signal 
than its corresponding cells that were kept in the dark, indicating an increase in 
Caspase 3/7 production. A Caspase 3/7 Fluorescence assay was used to measure cell 
death across different treatments on ARPE-19 cells.  To test the effects of resveratrol and 
pterostilbene on ARPE-19 cells Caspase 3/7 activation, resveratrol (50 & 100µM) and 
pterostilbene (10 & 25µM) were added to appropriate wells. Cells were pre-incubated 
with treatments, then exposed to blue light for 12 hours before media was removed and 
Caspase 3/7 Fluorescence detection reagent was added and incubated for 30 min before 
beginning the fluorescence readings. Along with fluorescence measurements, cell 
images were taken across all treatments to allow for a visual representation of Caspase 
3/7 in each treatment. Following the assay, values were plotted on a bar graph verses 
control cells which received no treatment. Figure 4.9 represents the results from the 
Caspase 3/7 assay testing the protective role of resveratrol and pterostilbene on ARPE-
19 cells exposed to blue light for 12 hours. Figure 4.10 shows the images that were taken 
under each treatment condition. As shown with MTS cell viability, resveratrol treatment 
at 50µM significantly (p<0.05) reduced the fluorescence activity in cells exposed to blue 
light indicating that there is a reduction in cellular apoptosis. Pterostilbene treatment of 
25µM showed an increase in fluorescence activity meaning that there was more cellular 
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apoptosis than that in cells that were exposed to blue light only. One possibility could 
be due to the structural changes occurring when pterostilbene is exposed to blue light. 
















Figure 4.9. Caspase 3/7 Fluorescence Assay. Caspase 3/7 activation using Caspase 3/7 
fluorescence assay. Cells were pre-treated for 4 hours with resveratrol 50µM & 100µM 
and pterostilbene 10µM & 25µM, followed by 12 hours of exposure to either blue light 









Figure 4.10. Cell Images from Caspase 3/7 Assay. Caspase 3/7 activation using Caspase 
3/7 fluorescence assay. Cells were pre-treated for 4 hours with resveratrol 50µM & 
100µM and pterostilbene 10µM & 25µM, followed by 12 hours of exposure to either 




4.5.3 Propidium Iodide Assay: resveratrol, pterostilbene and Blue Light  
 
Propidium Iodide (PI) staining was used to measure cell death across different 
treatments on ARPE-19 cells. Resveratrol (50 & 100µM) and pterostilbene (10 & 25µM) 
was added to appropriate wells. Cells were pre-incubated with treatments, then 
exposed to blue light for 12 hours before media was removed in order to perform 
Propidium Iodide staining and objective measurement using flow cytometry. Figure 
4.11 represents the results from the Propidium Iodide staining bar graphs testing the 
protective role of resveratrol and pterostilbene on ARPE-19 cells exposed to blue light 
for 12 hours. Resveratrol at 50µM and 100µM both significantly reduced the mean 
fluorescence intensity, indicating a decrease in cell death. Pterostilbene showed large 
increases in fluorescence intensity, indicating that more cell death took place. This could 




be due to the changes occurring when pterostilbene is exposed to blue light. These 
changes could be making the compound more cytotoxic resulting in more cell death. 
Figure 4.12 shows the histogram output via the flow cytometer following the reads 
indicating FSC-H fluorescence versus cell count. Population A indicates cells that have 
membrane damage. In the control panel, darkness, the only treatment that presents 
itself is the H2O2 positive control group. In the blue light panel, all treatment groups are 
present in population A. This indicates that blue light is inflicting the same damages to 
ARPE-19 cells as H2O2 exposure. Population B is normal unaffected cells, which can be 
seen as slightly reduced when compared to the control cells.  
 
Figure 4.11. Propidium Iodide Cell Death Assay. Cells were pre-treated for 4 hours 
with resveratrol 50µM & 100µM and pterostilbene 10µM & 25µM, followed by 12 hours 





Figure 4.12. Propidium Iodide Cell Death Assay Histograms. Representative 
histogram indicating FSC-H fluorescence versus cell count.  Cells were pre-treated for 4 
hours with resveratrol 50µM & 100µM and pterostilbene 10µM & 25µM, followed by 12 
hours of exposure to either blue light or kept in the dark.  
 
 
4.5.4 Effect of resveratrol, pterostilbene and Blue Light on 4HNE 
 Immunoblotting was used to measure the oxidative stress marker, 4HNE. 4HNE 
is a product of lipid peroxidation, which occurs when free radicals steal electrons from 
lipids in cell membrane. 4HNE protein adduct content was significantly increased in 
ARPE-19 cells exposed to blue light for 12 hours. Resveratrol was seen to minimize the 
increase of 4HNE within ARPE-19 cells exposed to 12 hours of blue light. Results from 
the positive control show similar results on reducing 4HNE content, indicating the need 





when exposed to blue light, again, suggesting it was becoming more cytotoxic to the 
cells. The results are summarized in Figure 4.13.  
Figure 4.13. Effect of Blue light, resveratrol and pterostilbene on 4HNE protein 
expression. Protein expression of 4HNE in control, positive control, resveratrol (50µM 
& 100µM) and pterostilbene (10µM & 25µM) treatments. Cells were pre-treated for 4 
hours with resveratrol 50µM or 100µM and pterostilbene 10µM or 25µM, followed by 
12 hours of exposure to either blue light or kept in the dark. Protein expression was 









4.5.5 Effect of resveratrol, pterostilbene and Blue Light on catalase 
 Immunoblotting was used to investigate antioxidant enzyme catalase. Catalase is 
an important enzyme that is responsible for the decomposition of H2O2 within cells. 
When H2O2 accumulates in the cell it leads to increases in oxidative stress and can lead 
to cell death. An increase in catalase concentration signifies that there is an increase in 
oxidative stress within the cell. Catalase content was significantly decreased in ARPE-19 
cells exposed to blue light for 12 hours. Resveratrol (50µM) was seen to minimize the 
increase of catalase within ARPE-19 cells exposed to 12 hours of blue light. Pterostilbene 
was shown to result in slightly higher catalase concentrations, compared to resveratrol, 
when exposed to blue light. The results are summarized in Figure 4.14. From these 
preliminary results we suspect that resveratrol is able to minimize cellular damage on 


















Figure 4.14. Effect of Blue light, resveratrol and pterostilbene on catalase protein 
expression. Protein expression of catalase in control, positive control, resveratrol (50µM 
& 100µM) and pterostilbene (10µM & 25µM) treatment. Cells were pre-treated for 4 
hours with resveratrol 50µM or 100µM and pterostilbene 10µM or 25µM, followed by 
12 hours of exposure to either blue light or kept in the dark. Protein expression was 










4.5.6 Effect of resveratrol, pterostilbene and Blue Light on MnSOD 
 Immunoblotting was used to investigate antioxidant protein marker MnSOD. 
MnSOD concentration increases with increased oxidative stress and ROS within cells. 
MnSOD assists in the breakdown of O2- radicals. MnSOD content was increased in 
ARPE-19 cells exposed to blue light for 12 hours. The 50 and 100µM treatment of 
resveratrol was seen to minimize the increase of MnSOD within ARPE-19 cells exposed 
to 12 hours of blue light. Pterostilbene illustrated similar MnSOD concentrations as 
resveratrol when exposed to blue light. The results are summarized in Figure 4.15 and 
Table 4.. Reduction in MnSOD concentrations suggests the overall reduction of 
oxidative stress in the cells. Resveratrol has shown in these preliminary results to act as 
























Figure 4.15. Effect of Blue light, resveratrol and pterostilbene on MnSOD protein 
expression. Protein expression of MnSOD in control, positive control, resveratrol (50µM 
& 100µM) and pterostilbene (10µM & 25µM) treatments. Cells were pre-treated for 4 
hours with resveratrol 50µM or 100µM and pterostilbene 10µM or 25µM, followed by 
12 hours of exposure to either blue light or kept in the dark. Protein expression was 








4.5.7 Effect of resveratrol, pterostilbene and Blue Light on Caspase-3 
 Immunoblotting was used to investigate apoptotic protein marker Caspase-3. 
Caspase-3 is a protein which is expressed during cellular apoptosis. Increase in 
Caspase-3 concentration would signify an increase in cellular damage and death. 
Caspase-3 content was increased in ARPE-19 cells exposed to blue light for 12 hours. 
The 50 and 100µM treatment of resveratrol was seen to minimize the concentration of 
Caspase-3 within ARPE-19 cells exposed to 12 hours of blue light when compared to 
control cells. Pterostilbene was shown to result in slightly higher Caspase-3 
concentrations, compared to resveratrol, when exposed to blue light. Results are 
summarized in Figure 4.16. Reduction in the Caspase-3 concentration by both 
resveratrol and pterostilbene suggest that they in fact have a protective role against blue 
light induced damage. These preliminary results show promising results for these 


















Figure 4.16. Effect of Blue light, resveratrol and pterostilbene on Caspase-3 protein 
expression. Protein expression of Caspase-3 in control, positive control, resveratrol 
(50µM & 100µM) and pterostilbene (10µM & 25µM) treatments. Cells were pre-treated 
for 4 hours with resveratrol 50µM or 100µM and pterostilbene 10µM or 25µM, followed 
by 12 hours of exposure to either blue light or kept in the dark. Protein expression was 



















Chapter 5: Discussion  
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Chapter 5:  
5.1 Discussion 
Age-Related Macular Degeneration (AMD) is a progressive eye disease.  AMD 
causes a blurred central vision making it difficult for diagnosed patients to see fine 
details and perform everyday tasks such as reading and driving. This condition affects a 
large portion of the population over the age of 50 (Moutray, T., et al. 2011., Colijn, J. M., 
et al. 2017).  
Resveratrol has been studied for its variety of therapeutic properties including 
antioxidative, anti-inflammatory, antitumorigenic, anticarcinogenic, antiaging, and 
cardioprotective (Burns, J., et al. 2002, Baur, J. A., et al. 2006).  Many studies suggest that 
resveratrol possesses strong antioxidant potential and is able to mitigate the damaging 
effects of ROS (Sinclair, D. A. 2006, Wu, H., et al.2018). Resveratrol has been studied 
extensively in cardiac modes of oxidative stress. Within the cardiac model systems 
resveratrol is able to inhibit cell death through the AMP-Activated Kinase (AMPK) 
pathway (Hwang, J. T., et al. 2008). Resveratrol has been studied in ARPE-19 cells for its 
ability to attenuate damage caused by H2O2. King, R. E., et al. (2005) showed that 50µM 
and 100µM treatments of resveratrol were able to significantly reduce the proliferation 
of ARPE-19 cells by 10% for 50µM treatments and 25% for 100µM treatments.  
An analog of resveratrol, pterostilbene, has also been studied and has shown 
promising results for reducing oxidative stress and acting as a strong antioxidant 
 79 
(McFadden, D. 2013, Li, Y. R., et al. 2018), being cardioprotective (Li, Y. R., et al. 2018), 
and possessing antitumor properties (McCormack, D., et al. 2012). The use of 
pterostilbene to treat AMD has not been investigated and future studies need to be 
done in order to determine its place as an adjuvant treatment for AMD alongside the 
established medications.  
Resveratrol based supplements have been used to treat wet (exudative) AMD in 
patients that had either refused or failed anti-VEGF injections for AMD. Longevinex 
was a supplement consisting 100mg of resveratrol designed to be used to promote 
health and longevity of organs of the body which are exposed to higher levels of 
oxidative stress and DNA damage (Richer, S., et al. 2013).  Results from these 
supplements showed an improvement of visual function and macular thickness (Richer, 
S., et al. 2013). This study was limited by the number of patients enrolled, but shows 
promising results for using resveratrol in treatments of both wet and dry AMD.  
 
5.2 Development of the Experimental Model 
Taylor, H. R., et al. (1990) showed that blue light can cause similar cell damage 
within the eye similar to that seen in AMD. Damage caused by blue light in the eye can 
lead to the accumulation of oxidative stress molecules and ultimately lead to cell death. 
In our study, blue light was delivered to cells in culture vessels by a specially designed 
apparatus that was supported on top of the cells in the tissue culture incubator. Two 
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prototypes of the apparatus existed over the course of this experiment. Prototype one 
(Figure 4.4) was designed to run off a 9-volt battery, however, over the course of our 
experiment the battery would lose capacity and the LED lights would not be emitting 
full-spectrum wavelengths and intensities. This problem was solved by connecting the 
LED panel to a 9-volt power supply which supplies a constant voltage of 9-volts to 
ensure no voltage drop will occur. The blue light delivered was able to cause a 
noticeable decrease in cell viability. Issues with the first prototype occurred when a 
second panel was added and more voltage was required. With the addition of a second 
panel too much heat was generated, leading to compete cell death.  
The second prototype of the blue light apparatus was built using a PCB 
computer board that had LEDs and resistors soldered directly to it, which allowed for 
exact permanent positioning of all the parts (Figure 4.6). To ensure proper airflow and 
heat dissipation around the cells, this panel was supported on top of the cell culture 
flask by machine screws which allowed for all sides to be open, rather than having the 
entire area above the cells closed off. The panel was supplied powered by a power 
supply which was kept external to the tissue culture incubator to ensure no extra heat 
was introduced into the system. In a study by Brandstetter, C., et al. (2015) blue light 
caused significant damage to ARPE-19 cells and increased apoptosis. The second 
prototype of the blue light apparatus was designed to ensure that the surface of the cells 
in the tissue culture vessel received an even coverage of blue light over the course of the 
 81 
experiment. The panel was able to cause a very strong decrease in cell viability as seen 
in Figure 4.7. ARPE-19 cells exposed to blue light for 12 hours showed a 56% reduction 
measured through MTS assay when comparing cells exposed to blue light for 12 hours 
to cells that were kept in a controlled setting (dark) for the same period of time. This 
significant (p<0.0001) reduction in cell viability shows how dangerous blue light is on 
retinal cells. Following successful optimization of the blue light apparatus, testing on 
cells with our two compounds could begin.  
MTS assay was used to assess cell viability. The MTS assay works by using a 
water-soluble tetrazolium salt, which is reduced inside the cell by dehydrogenase 
activities to give an orange-color formazan dye, which is soluble in the tissue culture 
media. The amount of the formazan dye, measured through absorbance readings, is 
directly proportional to the number of living cells. When compared to control cells, 
resveratrol was shown to have the ability to maintain cell viability by 43% (p<0.0001) in 
ARPE-19 cells that were exposed to blue light for 12 hours when compared to the blue 
light control (Figure 4.8). As suggested by Burns, J., et al. (2002) resveratrol’s 
antioxidant capacity may have promising results in diseases which are easily 
progressed by oxidative stress. Pterostilbene showed less promising results in the cell 
viability assay. Results were expected to be better than resveratrol due to its higher 
bioavailability within cells, however, that was not the case. When exposed to blue light, 
pterostilbene decreased cell viability when compared to the control cells (Figure 4.8).  
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Although not verified, a possibility of this reduction in viability could be due to a 
side reaction occurring and pterostilbene being broken down into compounds that are 
toxic to cells. One possibility causing the decrease in cell viability when pterostilbene is 
exposed to blue light is the methyl group acting as a leaving group. This leaving group 
would be able to bind to DNA within the cell causing DNA methylation. Methylation of 
the cell’s DNA would cause changes in function and ultimately could lead to cell death. 
In order to test this theory, further testing on the compound would have to be 
performed. Future testing could include High-Performance Liquid Chromatography 
(HPLC) which can be used to separate and identify components in a mixture. By using 
HPLC on the pterostilbene sample, we would be able to see any changes in structure 
that have occurred when exposed to blue light.  
Caspase 3/7 Fluorescence Detection reagent was used to monitor apoptosis 
within the cells exposed to blue light. Caspase 3/7 is a common apoptotic enzyme 
released by cells undergoing cell death. The green detection reagent works by having a 
four amino acid peptide bound to a nucleic acid binding dye. When Caspase 3/7 is 
present within the cell this activates the dye causing it to cleave the peptide, which 
allows it to be detected through fluorescence microscopy. From the fluorescence values 
obtained, a  50µM treatment of resveratrol significantly (p<0.05) reduced the Caspase 
3/7 activation in cells exposed to blue light when compared to control cells under the 
same conditions (Figure 4.9). Mean fluorescence intensity was reduced from 44762 to 
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41148 by the 50µM treatment of resveratrol. In a recent study by Ogawa, K., et al. (2014) 
Caspase 3/7 activity was decreased by polyphenols extracted from berries and fruit after 
being exposed to blue light for 6 hours (Ogawa, K., et al. 2014). In this study, 
pterostilbene again showed negative effects in protecting APRE-19 cells from blue light 
damage when compared to control cells of the same treatment. The fluorescence 
microscopy images (Figure 4.10) depict the trends observed in the fluorescence intensity 
(Figure 4.9) where green cells were positive for Caspase 3/7.  
Blue light exposure for 12 hours in ARPE-19 cells resulted in higher cell death 
and/or necrosis measured via flow cytometry. Necrosis is characterized by permeability 
changes in the mitochondrial membrane resulting in the breaking of the outer 
membrane releasing proteases into the cytosol (Ormerod, M. G., et al. 1993). Propidium 
Iodide (PI) is a membrane-impermeable dye that is only able to enter cells when 
membrane damage has occurred (Ormerod, M. G., et al. 1993). In this study, PI positive 
cells were increased when ARPE-19 cells were exposed to blue light for 12 hours, 
however, both 50µM and 100µM treatments of resveratrol were able to attenuate the 
damages caused by blue light when compared to the control cells (Figure 4.11). When 
exposed to blue light, pterostilbene exponentially increased the PI positive cells when 
compared to the control cells (Figure 4.11). Again, this could be due to a side reaction 
occurring and pterostilbene being broken down by the blue light wavelength into 
compounds that are toxic to cells. Representative histograms indicating FSC-H 
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fluorescence versus cell count (Figure 4.12) show a definitive shift in peaks when 
comparing the control (dark) to treatment (blue light) conditions.  
Overproduction of ROS within cells can lead to oxidative damage in cells 
including lipid peroxidation (Zhong, H., et al. 2015). Lipid peroxidation occurs when 
free radicals steal electrons from lipids in cell membranes. Lipid peroxidation can be 
measured through quantification of the lipid peroxidation product 4HNE (Zhong, H., et 
al. 2015). Measurement of 4HNE is quantified using protein adduct which are formed 
during times of oxidative stress within cells. In a study by Brandstetter, C., et al. (2015) 
4HNE protein adduct was increased in ARPE-19 cells exposed to blue light for 6 hours. 
In cells exposed to blue light, an increase in 4HNE production can be observed (Figure 
4.13). Resveratrol treatments of 50µM and 100µM showed noticeable decreases in 4HNE 
protein adduct formation when compared to control cells of the same condition. Again, 
as seen in the previous assays, pterostilbene treatments of 10µM and 25µM showed 
increases in 4HNE when compared to the control cells of the same condition. These 
preliminary western blots (n=1) suggest that resveratrol is able to reduce oxidative 
stress in blue light conditions.  
Antioxidants can scavenge damaging ROS molecules within cells in order to 
achieve a cellular redox balance. In this study, we investigated the protein expression of 
catalase, which promotes the conversion of H2O2 into H2O and O2. In a recent study by 
Arumugam, B., et al. (2019) ARPE-19 cells exposed to H2O2 saw a significant increase in 
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catalase concentration when compared to untreated cells. In our study, ARPE-19 cells 
that were exposed to blue light for 12 hours showed an increase in catalase 
concentration (Figure 4.14). Both concentrations of resveratrol was able to reduce the 
catalase concentrations when compared to control cells that were just exposed to blue 
light. Pterostilbene showed no improvement when comparing the catalase 
concentrations between control (dark) and treatment (blue light). This preliminary 
western blot (n=1) suggests that resveratrol is able to reduce oxidative stress in blue 
light conditions by acting as an antioxidant. 
We investigated the protein expression of MnSOD, which catalyzes the reduction 
of O2•- to H2O2 and O2. In a recent study by Arumugam, B., et al. (2019) ARPE-19 cells 
exposed to H2O2  saw a significant increase in MnSOD concentrations when compared 
to untreated cells. In our study, ARPE-19 cells that were exposed to blue light for 12 
hours showed an increase in MnSOD concentration (Figure 4.15). Cells that were 
treated with resveratrol showed a reduction in MnSOD concentrations when compared 
to the control cells. Pterostilbene showed no improvement when comparing the 
MnSOD concentrations between control (dark) and treatment (blue light). This 
preliminary western blot (n=1) suggests that resveratrol, again, is able to reduce 
oxidative stress in blue light conditions 
Caspase-3 is a common apoptotic protein released by cells undergoing cell death. 
In an early study by Sparrow, J. R., et al. (2001), blue light caused an increase in 
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Caspase-3 activity in ARPE-19 cells. In this study, Caspase-3 concentrations were seen 
to increase in ARPE-19 cells exposed blue light for 12 hours. Treatments of resveratrol 
were shown to minimize the concentrations of Caspase-3 when comparing the blue 
light treated cells to the control cells (Figure 4.16). Pterostilbene showed no 
improvement when comparing the Caspase-3 concentrations between control (dark) 
and treatment (blue light). This preliminary western blot (n=1) again suggests that 
resveratrol is able to reduce the early stages of apoptosis of cells in blue light conditions.  
 
5.3 Clinical Significance of this Project 
 Age-Related Macular Degeneration (AMD) is a progressive eye disease that 
causes a blurred central vision (Moutray, T., et al. 2011., Colijn, J. M., et al. 2017). AMD 
is the leading cause of blindness in Caucasian Americans over the age of 50. According 
to the Eye Disease Prevalence Group Study 54.4% of blindness in Americans is caused 
by AMD. As the aging population increases the number of AMD cases is projected to 
rise, resulting in more blind patients. Certain populations are at higher risk of getting 
AMD (Kenney, M. C., et al. 2013). Smoking introduces many free radicals into the body 
and can causes serious damage and increase the chance of getting AMD (Cheng, A. C., 
et al. 2000). Cigarettes causes vasoconstriction to the blood vessels which cuts down the 
supply of blood and oxygen to the eyes (Frayser, R., et al. 1964). The retina is at risk for 
oxidative stress as it has a high proportion of polyunsaturated fatty acids, high oxygen 
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consumption, and chronic exposure to visible and ultraviolet light spectrums. It is 
predicted that AMD is easily progressed by oxidative stress within the eyes, this study 
aimed to investigate oxidative stress caused by blue light, a growing concern in AMD 
progression.  
Two forms of AMD are commonly diagnosed in clinical settings, they are wet 
and dry AMD (Jager, R. D. et al.2008, Ambati, J., et al. 2012). Dry AMD is characterized 
by the formation of small yellow deposits in the macula called drusen. Wet AMD 
develops when there is the formation of blood vessels from the choroid layer into the 
macula, called choroidal neovascularization. These abnormal blood vessels can easily 
break and leak fluid and blood into the layers of the retina (Noble, J., et al. 2010, 
Bressler, N. M., et al. 1988). Fluid buildup can collect between the RPE layer and Bruch’s 
membrane causing structural changes in the RPE cell layer, altering the shape which 
leads to photoreceptor damage and severe vision loss.  
The dry form of AMD is usually treated with nutritional supplements, ensuring a 
balanced healthy diet with a high vitamin intake and antioxidants support the cells of 
the macula. Supplements are commonly prescribed to increase the concentration of 
vitamins and minerals known to support cell health (Bandello, F., et al. 2017).  (Age-
Related Eye Disease Study Research Group. 2003). 
The benefits of resveratrol are well documented in previous studies for 
numerous conditions. When investigating blue light damage resveratrol shows 
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promising results at minimizing the effects of oxidative stress on ARPE-19 cells. 
Although these results are preliminary findings, the evidence suggests resveratrol may 
have a strong role in the treatment of AMD. Pterostilbene failed to show positive results 
in our study. It’s cell damaging properties after being exposed to blue light suggest the 
possibility of a side reaction occurring and future experiments need to be performed. 
From this study we were able to propose a model for how resveratrol acts on ARPE-19 
cells under blue light conditions (Figure 5.1). Future experiments into the cytotoxic 
properties of pterostilbene following blue light exposure will be performed. By 
exposing the compound to blue light prior to treating the cells will determine if it is the 
compound specifically, or a product of chemical reactions that are occurring.  
 
 
Figure 5.1 Model of resveratrol: Blue light induces oxidative on ARPE-19 cells. 
Oxidative stress decreases proliferation, and increases necrosis and apoptosis. 
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Resveratrol acts to reduce oxidative stress on ARPE-19 cells that are exposed to blue 
light. 
5.4 Limitations  
 This study was performed using an in vitro model of blue light induced-cell 
damage and the results should be extrapolated accordingly. Preliminary results of cell 
survival and oxidative stress measuring protein expression show promising results, 
however, due to the ongoing COVID-19 pandemic, further studies could not be 
completed at this time.  
 
5.5 Delimitations 
 To minimize the challenges of using an in vitro model, human ARPE-19 cells 
were chosen in an attempt to match real world outcomes of this project. By performing 
in vitro studies, results from assays can be directly correlated to individual changes in 
compound concentration or procedural changes rather than many contributing external 











 Blue light can cause damage to the eyes and can lead to conditions like AMD. 
AMD is likely caused by a combination of oxidative stress, environmental factors, and 
genetic factors which can lead to cell damage, death, and ultimately vision loss. 
Resveratrol is an antioxidant present in grapes and blueberries that has been studied in 
other conditions where oxidative stress plays a role in disease progression. In this 
study, we investigated the role of resveratrol and its analog pterostilbene on cell 
viability (MTS), apoptosis markers (Caspase-3/7 assay), membrane integrity (PI), 
antioxidant signaling (catalase and MnSOD), reactive oxygen species (4HNE), and 
apoptosis signaling (Caspase-3). The results of the in vitro studies demonstrated that 
ARPE-19 cells were susceptible to damages caused by exposure to blue light for 12 
hours, as shown by decreases in cell viability and increases in membrane damage 
assays. Treatment with resveratrol mitigated the detrimental effects of blue light on 
ARPE-19 cells, suggesting a possible role for resveratrol as a protective agent in the 
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7.1 Future studies  
 
 Future studies aim to investigate the possibility of resveratrol being used in 
combination with current anti-VEGF drugs used clinically. By testing combination 
treatments of resveratrol and anti-VEGF drugs, a possible increase in effectiveness may 
be seen when treating patients with wet AMD. A secondary method of investigating the 
effects of resveratrol would be to perform the same tests outlined in this project on a 
secondary cell line. Lastly, future studies aim to investigate the mechanistic pathway of 
resveratrol is to look at gene knock out cells. It is suspected that resveratrol acts through 
either SIRT1, Survivin, BCL-2, or Ku-70 gene pathways. By creating ARPE-19 cell 
knockouts of each and performing the same tests that was covered in this project, it is 
expected that resveratrol would have little to no cellular protection on the knockout it 
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